Afya (NASDAQ:AFYA) Upgraded to Strong-Buy at Wall Street Zen

Key Points

• Wall Street Zen upgraded Afya to a "strong-buy", but the broader analyst mix remains cautious (one Buy, seven Holds) with a consensus price target of about $17.30.
• Afya reported an EPS beat of $0.41 vs. $0.36 but posted a material revenue miss (BRL147.08M) and issued FY‑2026 revenue guidance slightly below street estimates, creating near‑term downside risk to growth expectations.
• The board approved a R$307.4 million dividend (roughly 40% of consolidated net income), a significant cash return that may attract income‑focused investors.

Afya (NASDAQ:AFYA - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research note issued to investors on Saturday.

Several other brokerages also recently commented on AFYA. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Afya in a research report on Wednesday, January 21st. Sanford C. Bernstein raised shares of Afya to a "market perform" rating in a research note on Friday, January 16th. Bank of America cut shares of Afya from a "buy" rating to a "neutral" rating and reduced their price target for the stock from $22.00 to $17.00 in a report on Tuesday, February 24th. JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $22.00 price target (down from $24.50) on shares of Afya in a research note on Wednesday, January 7th. Finally, UBS Group reiterated a "neutral" rating and set a $16.00 price objective (down from $18.00) on shares of Afya in a report on Friday, January 16th. One equities research analyst has rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $17.30.

Afya Stock Up 1.9%

Shares of Afya stock opened at $13.76 on Friday. Afya has a one year low of $13.00 and a one year high of $19.90. The company has a debt-to-equity ratio of 0.21, a current ratio of 0.98 and a quick ratio of 0.98. The stock's 50-day moving average is $14.39 and its 200 day moving average is $14.77. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of 9.90, a PEG ratio of 0.60 and a beta of 0.52.

Afya (NASDAQ:AFYA - Get Free Report) last issued its earnings results on Thursday, March 12th. The company reported $0.41 earnings per share for the quarter, topping analysts' consensus estimates of $0.36 by $0.05. Afya had a return on equity of 18.45% and a net margin of 20.12%.The business had revenue of $147.08 million during the quarter, compared to the consensus estimate of $174.74 million. Equities research analysts anticipate that Afya will post 1.52 EPS for the current year.

Institutional Trading of Afya

Institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its position in shares of Afya by 167.3% during the first quarter. Goldman Sachs Group Inc. now owns 45,093 shares of the company's stock valued at $809,000 after purchasing an additional 28,226 shares in the last quarter. Geode Capital Management LLC grew its position in Afya by 85.1% in the 2nd quarter. Geode Capital Management LLC now owns 52,111 shares of the company's stock worth $931,000 after purchasing an additional 23,961 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Afya in the 2nd quarter worth about $391,000. Quadrature Capital Ltd purchased a new stake in Afya in the 2nd quarter valued at about $181,000. Finally, Quantbot Technologies LP purchased a new stake in Afya in the 2nd quarter valued at about $117,000. Institutional investors own 88.02% of the company's stock.

More Afya News

Here are the key news stories impacting Afya this week:

• Positive Sentiment: EPS beat — Afya reported $0.41 EPS for 4Q25, topping consensus estimates and last year’s EPS, signaling stronger profitability per share which supports valuation metrics. Afya (AFYA) Tops Q4 Earnings Estimates
• Positive Sentiment: Large cash return — the Board approved a R$307.4 million dividend (~40% of consolidated net income), which is supportive for income-focused shareholders and may attract yield-seeking demand. Afya Limited Announces Dividend Distribution of R$307.4 Million
• Neutral Sentiment: Management commentary/transcript available — the full Q4 2025 earnings call transcript provides additional color on growth drivers, margins and capital allocation; investors should review management’s remarks on enrollment trends and clinic operations. Afya Limited (AFYA) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Revenue miss — Afya reported 4Q revenue of BRL147.08 million (reported in USD-equivalent headlines), materially below analyst expectations, raising questions about enrollment or service revenue pacing that could pressure near-term growth. Afya Limited Announces Fourth Quarter and Twelve Months 2025 Financial Results
• Negative Sentiment: FY‑2026 revenue guidance slightly below consensus — the company updated FY‑2026 revenue guidance to a range (~R$731.7M–R$759.5M in the entry) that sits under the street’s ~$764M consensus, introducing downside risk to growth expectations; EPS guidance detail was unclear in the release. Afya Limited Announces Fourth Quarter and Twelve Months 2025 Financial Results

Afya Company Profile

Afya Ltd. operates as a leading provider of medical education and training services in Brazil. The company offers a comprehensive suite of educational programs that span undergraduate medical degrees, residency exam preparation, continuing medical education (CME) and digital learning platforms. Through a network of partner institutions and its own campus operations, Afya supports students at every stage of the medical training continuum, from enrollment in medical schools to ongoing professional development for practicing physicians.

At the core of Afya's offerings is its undergraduate medical program, delivered through a combination of in-person courses at affiliated campuses and fully digital curricula.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.